PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference taking place February 8 - 9, 2016 at the Waldorf Astoria in New York, NY. Ocera’s management will present at 10:00 AM ET on Tuesday, February 9th, in the Conrad room in the conference’s Orphan/Rare Diseases track.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Susan Sharpe Ocera Therapeutics, Inc. email@example.com 919-328-1109
Source:Ocera Therapeutics, Inc.